Meeting
2023 ASCO Annual Meeting
A phase II study of tinostamustine in patients (pts) with advanced solid tumours.
Authors
Anna Tinker
BC Cancer - Vancouver, Vancouver, BC, Canada
Anna Tinker , James Fredric Strauss , Reva Schneider , Rashmi Chugh , Giuseppe Curigliano , Massimo A. Di Nicola , Ana Oaknin , Tomas Janik , Kasia Hilgier , Nick Manamley , Shivaani Kummar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT03345485
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3021)
DOI
10.1200/JCO.2023.41.16_suppl.3021
Abstract #
3021
Poster Bd #
219
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).
First Author: Amita Patnaik
Poster
2022 ASCO Annual Meeting
Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
First Author: Sadakatsu Ikeda
Poster
2022 ASCO Annual Meeting
Feasibility of an explainable AI-based therapeutic recommendation-tool utilizing tumor gene expression profiles in advanced and refractory solid tumors.
First Author: Ouissam Al Jarroudi